FrancophonIA/ELRC3.0 huggingface dataset:
English: How to transfer patients taking levodopa/DDC inhibitor (carbidopa or benserazide) preparations and entacapone tablets to Corbilta a. Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Corbilta tablet strengths can be directly transferred to corresponding Corbilta tablets.
Estonian: a. Patsiendid, keda parajasti ravitakse entakapooni ja standardselt vabaneva levodopa/karbidopa preparaadiga annustes, mis on võrdsed Corbilta tableti toimeainete sisaldusega, võib kohe üle viia ravile Corbilta'ga.
English: Corbilta 150 mg/37.5 mg/200 mg: brownish or greyish red, elongated-ellipse shaped, unscored filmcoated tablets marked with ‘LCE 150' on one side.
Estonian: Corbilta 150 mg/37,5 mg/200 mg: pruunikas-või hallikaspunane, pikendatud ellipsi kujuline, poolitusjooneta õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 150”.
English: Corbilta 75 mg/18.75 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets).
Estonian: Corbilta 75 mg/18,75 mg/200 mg tabletid on saadaval viies erinevas pakendi suuruses (10, 30, 100, 130 või 175 tabletti).
English: Corbilta contains sucrose (2.3 mg/tablet).
Estonian: Corbilta sisaldab sahharoosi (2,3 mg/tabletis).
English: Corbilta contains sucrose (1.89 mg/tablet).
Estonian: Corbilta sisaldab sahharoosi (1,89 mg/tabletis).
English: - Periodic evaluation of hepatic, haematopoietic, cardiovascular and renal function is recommended during extended therapy with Corbilta.
Estonian: - Pikaajalise ravi korral Corbilta'ga on soovitatav perioodiliselt kontrollida maksa-, vereloome-, kardiovaskulaar- ja neerufunktsiooni.
English: When considered necessary, the replacement of Corbilta with levodopa and DDC inhibitor without entacapone or other dopaminergic treatment should proceed slowly and an increase in levodopa dose may be necessary.
Estonian: Seega peaks ravimi määrajad olema alati ettevaatlikud, kui asendavad Corbilta levodopa/DDC inhibiitoriga ilma entakapooni või muud dopamiinergilise toimega ravimit lisamata.
English: Corbilta 125 mg/31.25 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets).
Estonian: Corbilta 125 mg/31,25 mg/200 mg tabletid on saadaval viies erinevas pakendi suuruses (10, 30, 100, 130 või 175 tabletti).
English: Corbilta 75 mg/18.75 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 75' on one side.
Estonian: Corbilta 75 mg/18,75 mg/200 mg: hele pruunikaspunane, ovaalne õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 75”.
English: However, a direct switch from levodopa/DDC inhibitor to Corbilta is not recommended for patients who have dyskinesias or whose daily levodopa dose is above 800 mg.
Estonian: Seevastu ei ole kohene üleminek levodopa/DDC inhibiitoritelt Corbilta'le soovitatav patsientide puhul, kellel esineb düskineesia või kelle päevane levodopa annus ületab 800 mg. Neil juhtudel on soovitatav enne üleminekut ravile Corbilta'ga alustada ravi entakapooniga eraldi ravina (entakapooni sisaldavad tabletid) ja kohandada vajadusel levodopa annust.
English: Corbilta 125 mg/31.25 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 125' on one side.
Estonian: Corbilta 125 mg/31,25 mg/200 mg: hele pruunikaspunane, ovaalne õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 125”.
English: - Each Corbilta 75 mg/18.75 mg/200 mg tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Corbilta 75 mg/18,75 mg/200 mg tablett sisaldab 75 mg levodopat, 18,75 mg karbidopat ja 200 mg entakapooni.
English: Therefore, do not take Corbilta and iron supplements at the same time.
Estonian: Corbilta võib halvendada raua omastamist, seetõttu ärge võtke Corbilta't ja rauapreparaate samaaegselt.
English: Corbilta 175 mg/43.75 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets).
Estonian: Corbilta 175 mg/43,75 mg/200 mg tabletid on saadaval viies erinevas pakendi suuruses (10, 30, 100, 130 või 175 tabletti).
English: Corbilta 200 mg/50 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175).
Estonian: Corbilta 200 mg/50 mg/200 mg on saadaval viies erinevas pakendi suuruses (10, 30, 100, 130 ja 175 tabletti).
English: The safety of levodopa, carbidopa or entacapone in the infant is not known.
Estonian: Levodopa, karbidopa ja entakapooni ohutus imikule on teadmata ja seetõttu ei tohiks ema ravi ajal Corbilta'ga last imetada.
English: - Each Corbilta 125 mg/31.25 mg/200 mg tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Corbilta 125 mg/31,25 mg/200 mg tablett sisaldab 125 mg levodopat, 31,25 mg karbidopat ja 200 mg entakapooni.
English: Serious events of gastrointestinal haemorrhage (uncommon) and angioedema (rare) have been identified from the clinical trials with Corbilta or entacapone combined with levodopa/DDC inhibitor.
Estonian: Corbilta või entakapooni ja levodopa/DDC inhibiitori kombinatsioonravi kliinilistel uuringutel on tuvastatud ka raskeid seedetrakti verejookse (aeg-ajalt) ja angioödeemi (harv).
English: - Each Corbilta 150 mg/37.5 mg/200 mg tablet contains 150 mg of levodopa, 37.5 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Corbilta 150 mg/37,5 mg/200 mg tablett sisaldab 150 mg levodopat, 37,5 mg karbidopat ja 200 mg entakapooni.
English: - Each Corbilta 50 mg/12.5 mg/200 mg tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Corbilta 50 mg/12,5 mg/200 mg tablett sisaldab 50 mg levodopat, 12,5 mg karbidopat ja 200 mg entakapooni.
English: - Each Corbilta 175 mg/43.75 mg/200 mg tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Corbilta 175 mg/43,75 mg/200 mg tablett sisaldab 175 mg levodopat, 43,75 mg karbidopat ja 200 mg entakapooni.
English: - Each Corbilta 100 mg/25 mg/200 mg tablet contains 100 mg of levodopa, 25 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Corbilta 100 mg/25 mg/200 mg tablett sisaldab 100 mg levodopat, 25 mg karbidopat ja 200 mg entakapooni.
English: Corbilta 50 mg/12.5 mg/200 mg: brownish or greyish red, round, convex unscored film-coated tablets marked with ‘LCE 50' on one side.
Estonian: Corbilta 50 mg/12,5 mg/200 mg: pruunikas-või hallikaspunane, ümar, kumer poolitusjooneta õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 50”.
English: Corbilta contains sucrose (1.9 mg/tablet).
Estonian: Corbilta sisaldab sahharoosi (1,9 mg/tabletis).
English: If this happens, you should not drive or use any tools or machines (see also section 'Driving and using machines') - notice that uncontrolled movements begin or get worse after you started to take Corbilta.
Estonian: Sel juhul ei tohi te juhtida autot ega teisi masinaid (vt ka lõik „Autojuhtimine ja masinatega töötamine“) - te tunnete, et kontrollimatud liigutused algavad taas või muutuvad hullemaks peale ravi alustamist Corbilta'ga: võtke ühendust oma arstiga, sest vajalikuks võib osutuda parkinsonismivastaste ravimite annuse muutmine - tekib kõhulahtisus: jälgige oma kehakaalu, vältimaks võimalikku ulatuslikku kehakaalu langust - ilmneb suhteliselt lühikese aja jooksul progresseeruv isutus, asteenia (nõrkus, kurnatus) ja kaalulangus.
English: Corbilta 175 mg/43.75 mg/200 mg: light brownish red, oval, unscored film-coated tablets marked with ‘LCE 175' on one side.
Estonian: Corbilta 175 mg/43,75 mg/200 mg: hele pruunikaspunane, ovaalne poolitusjooneta õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 175”.
English: Corbilta 100 mg/25 mg/200 mg: brownish or greyish red, oval, unscored film-coated tablets marked with ‘LCE 100' on one side.
Estonian: Corbilta 100 mg/25 mg/200 mg: pruunikas-või hallikaspunane, ovaalne poolitusjooneta õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 100”.
English: Corbilta contains sucrose (1.6 mg/tablet).
Estonian: Corbilta sisaldab sahharoosi (1,6 mg/tabletis).
English: Corbilta contains sucrose (1.2 mg/tablet).
Estonian: Corbilta sisaldab sahharoosi (1,2 mg/tabletis).
English: Corbilta contains sucrose (1.4 mg/tablet).
Estonian: Corbilta sisaldab sahharoosi (1,4 mg/tabletis).
English: - Each Corbilta 200 mg/50 mg/200 mg tablet contains 200 mg of levodopa, 50 mg of carbidopa and 200 mg of entacapone.
Estonian: - Iga Corbilta 200 mg/50 mg/200 mg tablett sisaldab 200 mg levodopat, 50 mg karbidopat ja 200 mg entakapooni.
English: Corbilta 175 mg/43.75 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Estonian: Corbilta 175 mg/43,75 mg/200 mg õhukese polümeerikattega tabletid levodopa/karbidopa/entakapoon
English: EU/1/13/859/007 10 film-coated tablets EU/1/13/859/008 30 film-coated tablets EU/1/13/859/009 100 film-coated tablets EU/1/13/859/010 130 film-coated tablets EU/1/13/859/011 175 film-coated tablets
Estonian: EU/1/13/859/007 10 õhukese polümeerikattega tabletti EU/1/13/859/008 30 õhukese polümeerikattega tabletti EU/1/13/859/009 100 õhukese polümeerikattega tabletti EU/1/13/859/010 130 õhukese polümeerikattega tabletti EU/1/13/859/011 175 õhukese polümeerikattega tabletti
English: Corbilta 125 mg/31.25 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Estonian: Corbilta 125 mg/31,25 mg/200 mg õhukese polümeerikattega tabletid levodopa/karbidopa/entakapoon
English: Corbilta 75 mg/18.75 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Estonian: Corbilta 75 mg/18,75 mg/200 mg õhukese polümeerikattega tabletid levodopa/karbidopa/entakapoon
English: Corbilta 200 mg/50 mg/200 mg: dark brownish red, oval, unscored film-coated tablets marked with ‘LCE 200' on one side.
Estonian: Corbilta, 200 mg/50 mg/200 mg: tume pruunikaspunane, ovaalne poolitusjooneta õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 200”.
English: EU/1/13/859/023 10 film-coated tablets EU/1/13/859/024 30 film-coated tablets EU/1/13/859/025 100 film-coated tablets EU/1/13/859/026 130 film-coated tablets EU/1/13/859/027 175 film-coated tablets EU/1/13/859/028 250 film-coated tablets
Estonian: EU/1/13/859/023 10 õhukese polümeerikattega tabletti EU/1/13/859/024 30 õhukese polümeerikattega tabletti EU/1/13/859/025 100 õhukese polümeerikattega tabletti EU/1/13/859/026 130 õhukese polümeerikattega tabletti EU/1/13/859/027 175 õhukese polümeerikattega tabletti EU/1/13/859/028 250 õhukese polümeerikattega tabletti
English: EU/1/13/859/001 10 film-coated tablets EU/1/13/859/002 30 film-coated tablets EU/1/13/859/003 100 film-coated tablets EU/1/13/859/004 130 film-coated tablets EU/1/13/859/005 175 film-coated tablets EU/1/13/859/006 250 film-coated tablets
Estonian: EU/1/13/859/001 10 õhukese polümeerikattega tabletti EU/1/13/859/002 30 õhukese polümeerikattega tabletti EU/1/13/859/003 100 õhukese polümeerikattega tabletti EU/1/13/859/004 130 õhukese polümeerikattega tabletti EU/1/13/859/005 175 õhukese polümeerikattega tabletti EU/1/13/859/006 250 õhukese polümeerikattega tabletti
English: EU/1/13/859/034 10 film-coated tablets EU/1/13/859/035 30 film-coated tablets EU/1/13/859/036 100 film-coated tablets EU/1/13/859/037 130 film-coated tablets EU/1/13/859/038 175 film-coated tablets
Estonian: EU/1/13/859/034 10 õhukese polümeerikattega tabletti EU/1/13/859/035 30 õhukese polümeerikattega tabletti EU/1/13/859/036 100 õhukese polümeerikattega tabletti EU/1/13/859/037 130 õhukese polümeerikattega tabletti EU/1/13/859/038 175 õhukese polümeerikattega tablett
English: Corbilta 150 mg/37.5 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone
Estonian: Corbilta 150 mg/37,5 mg/200 mg õhukese polümeerikattega tabletid Levodopa/karbidopa/entakapoon
English: EU/1/13/859/018 10 film-coated tablets EU/1/13/859/019 30 film-coated tablets EU/1/13/859/020 100 film-coated tablets EU/1/13/859/021 130 film-coated tablets EU/1/13/859/022 175 film-coated tablets
Estonian: EU/1/13/859/018 10 õhukese polümeerikattega tabletti EU/1/13/859/019 30 õhukese polümeerikattega tabletti EU/1/13/859/020 100 õhukese polümeerikattega tabletti EU/1/13/859/021 130 õhukese polümeerikattega tabletti EU/1/13/859/022 175 õhukese polümeerikattega tabletti
English: Corbilta 50 mg/12.5 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Estonian: Corbilta 50 mg/12,5 mg/200 mg õhukese polümeerikattega tabletid Levodopa/karbidopa/entakapoon
English: Corbilta 50 mg/12.5 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone
Estonian: Corbilta 50 mg/12,5 mg/200 mg õhukese polümeerikattega tabletid levodopa/karbidopa/entakapoon
English: EU/1/13/859/029 10 film-coated tablets EU/1/13/859/030 30 film-coated tablets EU/1/13/859/031 100 film-coated tablets EU/1/13/859/032 130 film-coated tablets EU/1/13/859/033 175 film-coated tablets
Estonian: EU/1/13/859/029 10 õhukese polümeerikattega tabletti EU/1/13/859/030 30 õhukese polümeerikattega tabletti EU/1/13/859/031 100 õhukese polümeerikattega tabletti EU/1/13/859/032 130 õhukese polümeerikattega tabletti EU/1/13/859/033 175 õhukese polümeerikattega tabletti
English: EU/1/13/859/012 10 film-coated tablets EU/1/13/859/013 30 film-coated tablets EU/1/13/859/014 100 film-coated tablets EU/1/13/859/015 130 film-coated tablets EU/1/13/859/016 175 film-coated tablets EU/1/13/859/017 250 film-coated tablets
Estonian: EU/1/13/859/012 10 õhukese polümeerikattega tabletti EU/1/13/859/013 30 õhukese polümeerikattega tabletti EU/1/13/859/014 100 õhukese polümeerikattega tabletti EU/1/13/859/015 130 õhukese polümeerikattega tabletti EU/1/13/859/016 175 õhukese polümeerikattega tabletti EU/1/13/859/017 250 õhukese polümeerikattega tabletti
English: Corbilta 100 mg/25 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone
Estonian: Corbilta 100 mg/25 mg/200 mg õhukese polümeerikattega tabletid Levodopa/karbidopa/entakapoon
English: Corbilta 200 mg/50 mg/200 mg film-coated tablets Levodopa/carbidopa/entacapone
Estonian: Corbilta 200 mg/50 mg/200 mg õhukese polümeerikattega tabletid Levodopa/karbidopa/entakapoon
English: The European Commission granted a marketing authorisation valid throughout the European Union for Protelos on 21 September 2004.
Estonian: Euroopa Komisjon andis Protelose müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. septembril 2004.
English: Protelos is intended for long-term use.
Estonian: Protelos on ette nähtud pikaajaliseks kasutamiseks.
English: What measures are being taken to ensure the safe and effective use of Protelos?
Estonian: Mis meetmed võetakse, et tagada Protelose ohutu ja efektiivne kasutamine?
English: The full EPAR for Protelos can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Protelose kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Protelos is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Protelose võimalikult ohutu kasutamine.
English: Other information about Protelos
Estonian: Muu teave Protelose kohta
English: Protelos should be taken at least two hours after food, milk, milk products or calcium supplements, preferably at bedtime.
Estonian: Protelost manustatakse vähemalt 2 tundi pärast sööki või pärast piima või piimatoodete või kaltsiumi sisaldavate toidulisandite tarvitamist, eelistatavalt vahetult enne magamaminekut.
English: Protelos has been studied in almost 7,000 elderly women in two large studies.
Estonian: Protelost uuriti ligi 7000 eakal naisel kahes suures uuringus.
English: However, when looking only at women of 74 years of age or older with particularly weak thighbones, the results suggested a reduction of the risk of breaks in the hip with Protelos.
Estonian: Vaadeldes aga üksnes vähemalt 74-aastasi naisi, kelle reieluu oli eriti nõrk, näitasid tulemused puusamurdude riski vähenemist Protelose kasutamisel.
English: Protelos is taken as one sachet once a day.
Estonian: Protelost manustatakse üks kotike üks kord ööpäevas.
English: This is a summary of the European public assessment report (EPAR) for Protelos.
Estonian: See on ravimi Protelos Euroopa avaliku hindamisaruande kokkuvõte.
English: Overall, the results of the second study taken alone were insufficient to demonstrate a benefit of Protelos in preventing bone breaks.
Estonian: Üldiselt ei piisanud üksnes teise uuringu tulemustest Protelose kasulikkuse tõendamiseks luumurdude ennetamisel.
English: This showed that the risk of breaking a bone is reduced.
Estonian: See näitas luumurdude riski vähenemist.
English: The most common side effects with Protelos (which may affect more than 1 in 10 people) are hypersensitivity (allergic) skin reactions (rash, itching, urticaria or itchy rash, and swelling beneath the skin known as angioedema) and pain affecting muscles, bones and joints.
Estonian: Protelose kõige sagedamad kõrvalnähud (võivad esineda rohkem kui 1 patsiendil 10st) on ülitundlikkus (allergia), nahareaktsioonid (lööve, sügelus, nõgestõbi (sügelev lööve) ja angioödeem (nahaalune turse)) ning lihase-, luu- ja liigesevalu.
English: For more information about treatment with Protelos, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Protelosega toimuva ravi kohta lisateavet, lugege pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What is Protelos?
Estonian: Mis on Protelos?
English: Why has Protelos been approved?
Estonian: Miks Protelos heaks kiideti?
English: As there has been some data showing an increased risk of heart attack with Protelos, the decision to prescribe Protelos should take into account the patient's individual heart risk.
Estonian: Et andmed näitavad Protelose kasutamisel südameinfarkti suurenenud riski, tuleb Protelose määramise otsuses arvestada patsiendi individuaalset südameriski.
English: What is the risk associated with Protelos?
Estonian: Mis riskid Protelosega kaasnevad?
English: The CHMP decided that Protelos's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Protelose kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Protelos is a medicine that contains the active substance strontium ranelate.
Estonian: Protelos on ravim, mis sisaldab toimeainena strontsiumranelaati.
English: The company will also conduct a study to evaluate the effectiveness of the measures that have been put in place to reduce risk of heart and circulatory problems.
Estonian: Ravimi tootja korraldab ka uuringu, et hinnata kardiovaskulaarse riski vähendamiseks võetud meetmete tõhusust.
English: In the first study, this was based on the number of patients who, over three years, developed a new break in the spine, and in the second study, it was based on the number of patients who had a new bone break due to osteoporosis at any site other than the spine.
Estonian: Esimeses uuringus põhines näitaja nende patsientide arvul, kellel tekkis 3 aasta jooksul uus lülisambamurd, ja teises uuringus nende patsientide arvul, kellel tekkis uus osteoporoosist põhjustatud luumurd mujal peale lülisamba.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Protelos.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Protelos is used to treat severe osteoporosis (a disease that makes bones fragile) in post-menopausal women and men who have a high risk of fracture and cannot be treated with other medicines approved for osteoporosis.
Estonian: Protelost kasutatakse raske osteoporoosi (luu-urbnemuse) raviks luumurdude suure riskiga menopausijärgses eas naistel ja ka meestel, keda ei saa ravida muude osteoporoosiravimitega.
English: Protelos has also been compared with placebo in a main study involving 261 male patients at increased risk of breaking a bone.
Estonian: Protelost võrreldi platseeboga ka põhiuuringus, milles osales 261 luumurdude suurenenud riskiga meest.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Protelos, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Protelose ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: When looking at results of the two studies taken together, fewer women in the Protelos group developed breaks at any site outside the spine (including the hip) than in the placebo group (331 out of 3,295 with Protelos compared with 389 out of 3,256 for placebo).
Estonian: Kahe uuringu tulemusi ühendades oli Protelost kasutanud rühmas võrreldes platseeborühmaga vähem naisi, kellel tekkis osteoporoosist põhjustatud murde mujal kui lülisambas (sealhulgas puusamurde; luumurd tekkis 3295 Protelost kasutanud naisest 331-l ja 3256 platseebot kasutanud naisest 389-l).
English: In addition, education materials are sent to patients and healthcare professionals prescribing Protelos reminding them of the risk of heart and circulatory problems with the medicine and of the need for regular monitoring.
Estonian: Lisaks varustatakse patsiendid ja Protelost määravad arstid teabepakmega, milles rõhutatakse ravimiga seotud kardiovaskulaarset riski ja patsiendi pideva jälgimise vajadust.
English: Protelos must not be used in patients who have or have had venous thromboembolic events (problems due to the formation of blood clots in the veins, such as in the legs or lungs).
Estonian: Seda ei tohi kasutada ka patsiendid, kellel esineb või on esinenud venoosset trombembooliat (nt jalavõi kopsuveenides moodustunud trombidest põhjustatud tervisehäire).
English: In both studies, Protelos was compared with placebo (a dummy treatment) and the main measure of effectiveness was the reduction in the risk of a new bone break with Protelos.
Estonian: Mõlemas uuringus võrreldi Protelost platseeboga (näiv ravim) ja efektiivsuse põhinäitaja oli uue luumurru tõenäosuse vähenemine Protelose kasutamisel.
English: What benefit has Protelos shown during the studies?
Estonian: Milles seisneb uuringute põhjal Protelose kasulikkus?
English: In the study in male patients, the bone density in the lower part of the spine increased by 7% after one year of treatment in patients taking Protelos, compared with an increase of 1.7% in patients taking placebo.
Estonian: Meeste uuringutes oli patsiente, kellel suurenes lülisamba alaosa luutihedus pärast 1-aastast ravi, Protelose rühmas 7% ja platseeborühmas 1,7%.
English: In order to reduce the risk of heart attack, Protelos must also not be used in patients with high blood pressure that is not properly controlled or in patients with a current or past history of any of the following:
Estonian: Et vähendada südameinfarkti riski, ei tohi Protelost kasutada ohjamata hüpertensiooniga patsiendid ja patsiendid, kellel on või on esinenud järgmisi seisundeid:
English: For the full list of all side effects reported with Protelos, see the package leaflet.
Estonian: Protelose kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: In the first study, Protelos reduced the risk of new breaks in the spine by 41% over three years: 21% of the 719 women who took Protelos developed a new break in the spine, compared with 33% of the 723 who took placebo.
Estonian: Naisi, kellel tekkis uus lülisambamurd, oli Protelose rühma 719 naisest 21% ja platseeborühma 723 naisest 33%.
English: EPAR summary for the public strontium ranelate
Estonian: Protelos strontsiumranelaat
English: In postmenopausal women, Protelos reduces the risk of vertebral and hip fractures.
Estonian: Protelos vähendab menopausijärgses eas naistel lülisamba- ja puusamurdude riski.
English: What is Protelos used for?
Estonian: Milleks Protelost kasutatakse?